Equity Overview
Price & Market Data
Price: $12.56
Daily Change: -$0.31 / 2.47%
Range: $12.33 - $13.06
Market Cap: $470,252,704
Volume: 131,458
Performance Metrics
1 Week: -0.16%
1 Month: 29.35%
3 Months: 13.26%
6 Months: -47.34%
1 Year: -40.67%
YTD: -35.22%
Company Details
Employees: 28
Sector: Commercial services
Industry: Miscellaneous commercial services
Country:
Details
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.